GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellerophon Therapeutics Inc (OTCPK:BLPH) » Definitions » Asset Turnover

Bellerophon Therapeutics (Bellerophon Therapeutics) Asset Turnover : 0.00 (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Bellerophon Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Bellerophon Therapeutics's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Bellerophon Therapeutics's Total Assets for the quarter that ended in Sep. 2023 was $8.11 Mil. Therefore, Bellerophon Therapeutics's Asset Turnover for the quarter that ended in Sep. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Bellerophon Therapeutics's annualized ROE % for the quarter that ended in Sep. 2023 was -164.43%. It is also linked to ROA % through Du Pont Formula. Bellerophon Therapeutics's annualized ROA % for the quarter that ended in Sep. 2023 was -94.72%.


Bellerophon Therapeutics Asset Turnover Historical Data

The historical data trend for Bellerophon Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellerophon Therapeutics Asset Turnover Chart

Bellerophon Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bellerophon Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.47 - -

Competitive Comparison of Bellerophon Therapeutics's Asset Turnover

For the Biotechnology subindustry, Bellerophon Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellerophon Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bellerophon Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Bellerophon Therapeutics's Asset Turnover falls into.



Bellerophon Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Bellerophon Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0/( (26.875+7.935)/ 2 )
=0/17.405
=0.00

Bellerophon Therapeutics's Asset Turnover for the quarter that ended in Sep. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=0/( (11.245+4.979)/ 2 )
=0/8.112
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Bellerophon Therapeutics  (OTCPK:BLPH) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Bellerophon Therapeutics's annulized ROE % for the quarter that ended in Sep. 2023 is

ROE %**(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-7.684/4.673
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-7.684 / 0)*(0 / 8.112)*(8.112/ 4.673)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.7359
=ROA %*Equity Multiplier
=-94.72 %*1.7359
=-164.43 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Bellerophon Therapeutics's annulized ROA % for the quarter that ended in Sep. 2023 is

ROA %(Q: Sep. 2023 )
=Net Income/Total Assets
=-7.684/8.112
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-7.684 / 0)*(0 / 8.112)
=Net Margin %*Asset Turnover
= %*0
=-94.72 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Bellerophon Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Bellerophon Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellerophon Therapeutics (Bellerophon Therapeutics) Business Description

Traded in Other Exchanges
Address
184 Liberty Corner Road, Suite 302, Warren, NJ, USA, 07059
Bellerophon Therapeutics Inc is a clinical-stage therapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company's products are aimed at the treatment of different kinds of pulmonary hypertension.
Executives
Puissance Life Science Opportunities Fund Vi 10 percent owner 950 THIRD AVENUE, FL 25, NEW YORK NY 10022
Naseem Amin director 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Mary Ann Cloyd director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Theodore T Wang director C/O PUISSANCE CAPITAL MANAGEMENT LP, 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott P Bruder director C/O BELLEROPHON THERAPEUTICS, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Crispin Teufel director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Puissance Capital Fund (gp) Llc 10 percent owner 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Parag Suresh Shah officer: VP of Business Operations C/O BELLEROPHON THERAPEUTICS, INC., 184 LIBERTY CORNER ROAD, SUITE 302, NEW JERSEY NJ 07059
Martin Dekker officer: See Remarks 53 FRONTAGE ROAD, SUITE 301, PERRYVILLE III CORPORATE PARK, HAMPTON NJ 08827
Peter Fernandes officer: See Remarks PERRYVILLE III CORPORATE PARK, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Bobae Kim officer: VP Reg. Affairs & Quality 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Nicholas Laccona officer: Controller, (PFO & PAO) 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Steven B Klinsky 10 percent owner C/O NEW MOUNTAIN CAPITAL, L.L.C., 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Capital, L.l.c. 10 percent owner 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Investments Ii, Llc 10 percent owner 787 SEVENTH AVENUE, 49TH FLOOR, NEW YORK NY 10019

Bellerophon Therapeutics (Bellerophon Therapeutics) Headlines

From GuruFocus